SCHEMBL13699537

SCHEMBL13699537

OCCN(Cc1ccccc1)C[C@@H](O)c1ccc(Br)cc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.47
IGF1R P08069 3/20 0.44
TSHR P16473 1/20 0.44
HTT P42858 1/20 0.43
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
KDM4E B2RXH2 3/20 0.40
HSD17B10 Q99714 1/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
AOC3 Q16853 2/20 0.39
CNR2 P34972 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4164073 1.00 ALDH1A1 (0.47) ALDH1A1GAAMAPTMAPK1IGF1R
SCHEMBL8557986 0.90 ALDH1A1 (0.52) ALDH1A1GAAMAPTMAPK1TSHR
SCHEMBL13699528 0.90 ALDH1A1 (0.52) ALDH1A1GAAMAPTMAPK1TSHR
Hydrochloric Acid SCHEMBL3273754 0.88 ALDH1A1 (0.54) ALDH1A1GAAMAPTMAPK1TSHR
SCHEMBL13891162 0.86 HTT (0.50) ALDH1A1GAAMAPTMAPK1TSHR
SCHEMBL13891221 0.86 HTT (0.50) ALDH1A1GAAMAPTMAPK1TSHR
SCHEMBL3275466 0.86 ALDH1A1 (0.47) ALDH1A1GAAMAPTMAPK1TSHR
Hydrochloric Acid SCHEMBL3279850 0.84 ALDH1A1 (0.49) ALDH1A1GAAMAPTMAPK1TSHR
SCHEMBL13891219 0.82 ALDH1A1 (0.47) ALDH1A1GAAMAPTMAPK1TSHR
SCHEMBL17224115 0.81 ALDH1A1 (0.48) ALDH1A1GAAMAPTMAPK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221582-A1 Piperazine Derivatives And Their Use In Therapy VERNALIS (R&D) (GB) 2009-09-03 US disclosed
US-20090221582-A1 Piperazine Derivatives And Their Use In Therapy VERNALIS (R&D) (GB) 2009-09-03 US disclosed
WO-2007057687-A1 PIPERAZINE DERIVATIVES AND THEIR USE IN THERAPY VERNALIS (R & D) LIMITED (GB) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221582-A1 Piperazine Derivatives And Their Use In Therapy CNR2, CNR1, ALK ALDH1A1 1066/4885GAA 3365/4885MAPT 3800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.